Navigation Links
Jennerex Reports Positive Mechanistic Proof-of-Concept Clinical Trial Results Using JX-594 to Treat Metastatic Melanoma
Date:8/2/2011

nd currently markets nine products. Lee's Pharma focuses on several different areas such as cardiovascular and infectious diseases, dermatology, oncology, gynecology and others. It has more than 30 products under different development stages stemming from both internal R&D as well as from the recent acquisition of licensing and distribution rights from various U.S. and European companies. The mission of Lee's is to become a successful biopharmaceutical group in Asia providing innovative products to fight diseases and improve health and quality of life. Additional information about Lee's Pharma is available on the internet at www.leespharm.com.

About Jennerex

Jennerex, Inc. is a clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class, breakthrough targeted oncolytic products for cancer. The Company's lead product JX-594 is currently in two Phase 2 clinical trials in patients with primary liver cancer—an international, randomized, Phase 2 clinical trial, and a Phase 2 study of JX-594 in combination with sorafenib. Published studies designed to establish optimal dose levels and the safety profile of JX-594 have shown its ability to selectively target and cause destruction of a variety of common cancer types. JX-594 and other product candidates under development are designed to attack cancer tumors through three diverse mechanisms of action: the lysis of cancer cells through viral replication, the ablation of the blood supply to tumors through vascular targeting and destruction and the stimulation of the body's immune response against the cancer. Jennerex is headquartered in San Francisco and has related research and development operations in Ottawa, Canada and Pusan, South Korea. For more information about Jennerex, please visit www.jennerex.com.


'/>"/>
SOURCE Jennerex, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Jennerex and Partners Present Positive JX-594 Randomized Phase 2 Clinical Data Showing Promising Survival Benefit in Patients with Advanced Liver Cancer
2. Jennerex to Present JX-594 Liver Cancer Clinical Data at American Society of Gene and Cell Therapy Meeting
3. Jennerex Appoints James M. Burke, M.D. Vice President, Clinical Research
4. Jennerex and Transgene Enter Into an Exclusive Partnership for the Development and Commercialization of JX-594 for the Treatment of Cancers
5. Jennerex Completes Fully Subscribed Private Placement for Aggregate Gross Proceeds of $8.6 Million
6. Jennerex Reports Positive Phase 1 Results for JX-594 Administered Intravenously
7. Jennerex Adds Industry Veteran Paul Cleveland to Board of Directors
8. Jennerex Completes Over-Subscribed Series C Financing for Aggregate Gross Proceeds of Over $5.5 Million
9. Jennerex Closes $5 Million First Tranche of Series C Financing
10. Nature Reviews Publishes Article About Jennerexs Multi-Mechanistic Cancer Therapeutic
11. Jennerex Appoints Samantha Miller as Vice President of Corporate Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... November 26, 2014 The North ... segments the market for detailed analysis of the ... market to reach $616.3 million by 2018, growing ... 2018. , Browse through the TOC of the ... get an idea of the in-depth analysis and ...
(Date:11/26/2014)... -- The announced sales of three healthcare units within ... expand in non-healthcare areas, says Kalorama Information. Siemens hasn,t ... says that  Siemens is the third largest company in ... IVD market , with 5.5 billion in IVD revenues ... likely affect IVD market shares.  Siemens ...
(Date:11/26/2014)... 26, 2014 The Alliance for ... survey of European physicians at the "1 ST ... Biological Therapies" at the Spanish Ministry of Health, ... EuropaBio and the Spanish Bioindustry Association (ASEBIO), included ... from Spanish oncology and rheumatology societies, representatives from ...
(Date:11/26/2014)... November 26, 2014 The ETC ... award-winning technology innovation centers, announced today that applications ... on December 1st. “Do you have a big ... I want to know about it. AccelerateBaltimore helps ... to product in just 13 weeks.” Interested ...
Breaking Biology Technology:The North America Thermal Protective Clothing Market is estimated to grow up to $616.3 million by 2018 - Report by MicroMarket Monitor 2The North America Thermal Protective Clothing Market is estimated to grow up to $616.3 million by 2018 - Report by MicroMarket Monitor 3Kalorama: Sale of Three Siemens Healthcare Units Raises Questions About Firm's IVD Future 2ASBM Presents European Physicians Survey at Spanish Ministry of Health 2AccelerateBaltimore Applications to Close in 6 Days 2AccelerateBaltimore Applications to Close in 6 Days 3
... , IRVINE, Calif., Dec. 4 BlueFire Ethanol Fuels, Inc. (OTC ... fuel paradigm through the production of ethanol from non-food cellulosic wastes, ... list of the "50 Hottest Companies in Bioenergy;" the company,s second ... BlueFire Ethanol among the top 20 bioenergy companies for two straight ...
... PHILADELPHIA, Dec. 3 Shire plc (LSE: SHP, Nasdaq: ... voluntary recall of five lots and voluntary market withdrawal of ... . Shire is taking this action because some Daytrana patches ... their release liner removal specification, and as a result, patients ...
... , COLUMBIA, Md., Dec. 2 Martek Biosciences Corporation ... the results of its fourth quarter and fiscal year 2009 on ... Following the release, at 4:45 p.m. ET Martek will conduct a ... parties may listen to the call live via webcast by visiting ...
Cached Biology Technology:BlueFire Named One of Top 20 Bioenergy Companies for Second Consecutive Year 2BlueFire Named One of Top 20 Bioenergy Companies for Second Consecutive Year 3BlueFire Named One of Top 20 Bioenergy Companies for Second Consecutive Year 4Non-safety-related voluntary recall of a limited portion of Daytrana(R) (methylphenidate transdermal system) patches announced 2Non-safety-related voluntary recall of a limited portion of Daytrana(R) (methylphenidate transdermal system) patches announced 3Non-safety-related voluntary recall of a limited portion of Daytrana(R) (methylphenidate transdermal system) patches announced 4Non-safety-related voluntary recall of a limited portion of Daytrana(R) (methylphenidate transdermal system) patches announced 5Martek to Announce Fourth Quarter and Fiscal Year 2009 Results 2
(Date:11/21/2014)... -- C-Labs LLC, a leading provider of remote and ... announced the appointment of John Traynor to ... advisor to the firm, Mr. Traynor will now oversee ... out of the C-Labs office in Redmond, ... , Chief Executive Officer. Photo - ...
(Date:11/18/2014)... , Nov. 18, 2014   EyeLock ... authentication solutions, and MorphoTrust USA (Safran), ... services, today announced a strategic partnership to offer ... motor vehicle administration (MVA), airport screening and financial ... identity-related solutions, MorphoTrust serves consumers through a nationwide ...
(Date:11/7/2014)... associate professor, biomedical engineering, in the Grove School ... York, have identified a molecule that could lead ... aggressive forms of breast cancer. , Triple negative ... owing to aggressive proliferation and metastasis and a ... team, discovered the overexpression of intercellular adhesion molecule-1 ...
Breaking Biology News(10 mins):C-Labs Names Former Microsoft and Bsquare Executive as Chief Operating Officer 2EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 2EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 3
... from Johns Hopkins has convinced an international group of ... biomarkers and instead begin a 7,000-hour slog through a ... decode and analyze the molecules that might herald the ... resources available for the exhaustive and expensive testing that ...
... an imprint of Elsevier, announced today that its flagship journal, ... and The American Journal of Human Genetics , were ... in Biology and Medicine of the past century. The ... the SLA,s Biomedical and Life Sciences Division (DBIO) on the ...
... new study by researchers from UC Santa Barbara,s National Center ... threats to the world,s endangered coral reef ecosystems can be ... journal Coral Reefs , lead authors Kimberly A. Selkoe ... maps of the Northwestern Hawaiian Islands (NWHI) a vast ...
Cached Biology News:Compendium of pancreatic cancer biomarkers established as strategic approach to early-detection 2Compendium of pancreatic cancer biomarkers established as strategic approach to early-detection 33 prominent Cell Press journals named among the 100 most influential journals in past 100 years 2The fragility of the world's coral is revealed through a study of the Northwestern Hawaiian Islands 2The fragility of the world's coral is revealed through a study of the Northwestern Hawaiian Islands 3
Printer paper for Model 680 series readers is used with the thermal printers of the Model 680 and Model 680 XR microplate readers. Supplied as 2 rolls....
... cell, wide format, is used for vertical electrophoresis applications. ... and requires 1.2 L of running buffer. It includes ... mm IPG conversion kit, which contains accessories for use ... of IPG clamps, 2 sets of 20 x 20 ...
Includes PROTEAN II xi Basic unit and IPG conversion kit PROTEAN II XL Cell, wide format, Compatible with ReadyStrip IPG Strips 1.0 mm 165-3188 1.5 mm 165-3189 2.0 mm 165-3190...
... This depletion cocktail is ... cells from suspensions of rat ... using the StemSep (or compatible ... system. The T cell content ...
Biology Products: